Issue 18 - May 2, 2018
  • Flatiron, BMS form collaboration to curate regulatory-grade real-world data

    Bristol-Myers Squibb and Flatiron Health announced a three-year collaboration to advance methodologies for the curation of real-world data for cancer research and to develop regulatory-grade information.

    BMS will use Flatiron data to analyze real-world evidence across a range of tumors and will collaborate on the development and validation of real-world endpoints within Flatiron’s longitudinal datasets.

  • Conversation with The Cancer Letter

    BMS’s Saha: We’re at the start of defining new endpoints, hypotheses with real-world evidence

    Bristol-Myers Squibb’s three-year collaboration with Flatiron Health will focus on leveraging real-world data to improve the pharmaceutical company’s regulatory submissions, demonstrate the economic value of BMS’s cancer portfolio, and to study the predictive value of biomarkers.

  • Conversation with The Cancer Letter

    Oklahoma’s Stephenson Cancer Center earns coveted NCI Cancer Center designation

    The Stephenson Cancer Center at the University of Oklahoma May 2 announced that it has received Cancer Center designation from NCI.

    This designation brings the total number of NCI designated cancer centers to 70. With Stephenson included, 14 of these centers now have the Cancer Center designation, 49 have the Comprehensive Cancer Center designation, and seven have the Basic Laboratory Cancer Center designation.


  • In Brief

    • National Coalition for Cancer Research to cease operations as member groups take on their own education, policy roles
    • Campaign to educate Washington, DC, public about clinical trials
  • Funding Opportunities

    CPRIT announces New Seed Award for early-stage oncology startups

    The Cancer Prevention and Research Institute of Texas is unveiling a new award mechanism targeting early-stage oncology startup companies. Under this program, known as the Seed Award, companies can apply for up to $3 million in nondilutive funding to support development of innovative cancer therapeutics, diagnostics or tools.

  • TCCL Logo

  • New data prompts CDC to examine adequacy of pre-op workup by gynecologists

    In response to a congressional letter and a new study on the prevalence of undiagnosed hidden uterine cancers, officials at the Centers for Disease Control and Prevention are considering launching a review of whether gynecologists are sufficiently thorough in evaluating patients in the preoperative setting, according to insiders with knowledge of the agency’s plans.

  • Clinical Roundup

    • Keytruda meets ORR endpoint in interim analysis of phase III trial in NSCLC
  • Drugs and Targets

    • Novartis’ Kymriah gets second FDA approval—for large B-cell lymphoma
    • FDA approves Tafinlar and Mekinist for BRAF V600-mutant melanoma
    • FDA grants priority review to cemiplimab in advanced cutaneous squamous cell carcinoma
    • Genocea files IND for neoantigen cancer vaccine candidate GEN-009
  • CTEP Protocols

    NCI Trials for May

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

Issue 17 - Apr 27, 2018
Issue 16 - Apr 20, 2018
  • Sharpless adds $100 million to NCI’s RPG pool, R01s for young investigators boosted by 25%

    NCI will bump up the budget for its Research Project Grant pool by $100 million in 2018—the largest increase to the institute’s RPG pool since 2003, NCI Director Norman “Ned” Sharpless said at the annual meeting of the American Association for Cancer Research in Chicago.

    “This is possible thanks to increases in the past three years in our congressionally appropriated budget,” Sharpless said in his first public speech as NCI director at the meeting April 16. “While this is not solely for basic science—there are lots of laudable clinical trials and health services research funded from the RPG pool—this is the most straightforward way to assure we continue to fund investigator-initiated basic science.”

  • Piantadosi leaves Cedars-Sinai for Alliance and Harvard

    Steven Piantadosi is moving to Alliance, where he will serve as the associate group chair for strategic initiatives and innovation.

  • In Brief

    • SU2C focuses on precursor conditions in multiple myeloma
    • St. Baldrick’s commits $8 million to SU2C Pediatric Cancer Dream Team
    • Isabella Santos Foundation gives $5 million for rare & solid tumor program at Levine Children’s Hospital
    • MedStar Georgetown offers proton therapy with HYPERSCAN technology for adults and kids with cancer
    • Reprocell and Fox Chase to open biosample repository in India
  • TCCL Logo

  • Clinical Roundup

    • Keytruda combination improved OS regardless of PD-L1 expression, including patients who tested negative for PD-L1
    • Keytruda reduced risk of recurrence or death by over 40% vs. placebo as adjuvant therapy in resected, high-risk stage III melanoma
    • SU2C researchers find treatment strategy for stage I-III NSCLC
  • Drugs and Targets

    • FDA approves Tagrisso for front-line metastatic NSCLC with common EGFR mutations
    • FDA approves Opdivo and Yervoy for front-line advanced RCC
    • FDA approves Tavalisse for ITP
    • FDA issues guidance on investigational in vitro diagnostics in oncology trials
  • CTEP Protocols

    NCI Trials for April

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.